問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

陳彩雲

List

152Cases

2019-12-01 - 2025-12-31

Phase III

Active
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia

  • Condition/Disease

    Untreated Chronic Lymphocytic Leukemia

  • Test Drug

    Acalabrutinib (ACP-196)

Participate Sites
9Sites

Recruiting4Sites

Terminated5Sites

2022-04-01 - 2027-03-26

Phase III

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU) cancer associated VTE (Magnolia)

  • Condition/Disease

    Venous Thromboembolism

  • Test Drug

    abelacimab

Participate Sites
1Sites

Recruiting1Sites

2024-02-01 - 2038-01-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    EpcoritamabLenalidomideObinutuzumab RituximabCyclophosphamideDoxorubicinVincristineVincristinePrednisoneBendamustine

Participate Sites
4Sites

Recruiting4Sites

2020-10-01 - 2025-12-31

Phase I

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

  • Condition/Disease

    Relapsed/Refractory Acute Myeloid Leukemia

  • Test Drug

    RO7283420

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2012-06-30 - 2019-06-30

Phase III

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Condition/Disease

    Previously Undiagnosed Peripheral T-cell Lymphoma

  • Test Drug

    Pralatrexate

Participate Sites
8Sites

Terminated8Sites

2017-03-01 - 2019-09-30

Phase II

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Condition/Disease

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Test Drug

    SP-02L

Participate Sites
6Sites

Terminated5Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

2019-10-31 - 2022-02-04

Phase II

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract.

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    JNJ-53718678

Participate Sites
4Sites

Suspended4Sites

2013-09-01 - 2019-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma(DLBCL)

  • Test Drug

    Ibrutinib

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2012-11-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 8 9 10 11 12 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB